Georg Lindner, Annika Walter, Clara L Magnus, Katharina Rosenhammer, Bohdan Holoborodko, Victoria Koch, Sarah Hirsch, Luis Grossmann, Suqi Li, David M Knipe, Neal DeLuca, Beatrice Schuler-Thurner, Stefanie Gross, Barbara Schwertner, Martina Toelge, Anette Rohrhofer, Sabine Stöckl, Richard J Bauer, Gertrud Knoll, Martin Ehrenschwender, Sebastian Haferkamp, Barbara Schmidt, Philipp Schuster
In 2015, the oncolytic herpes simplex virus 1 (HSV-1) T-VEC (talimogene laherparepvec) was approved for intratumoral injection in non-resectable malignant melanoma. To determine whether viral replication is required for oncolytic activity, we compared replication-deficient HSV-1 d106S with replication-competent T-VEC. High infectious doses of HSV-1 d106S killed melanoma (n = 10), head-and-neck squamous cell carcinoma (n = 11), and chondrosarcoma cell lines (n = 2) significantly faster than T-VEC as measured by MTT metabolic activity, while low doses of T-VEC were more effective over time...
March 5, 2024: Immunology